Immunocore (NASDAQ:IMCR) Sets New 1-Year Low at $25.30

Immunocore Holdings plc (NASDAQ:IMCR) shares reached a new 52-week low on Thursday . The stock traded as low as $25.30 and last traded at $25.76, with a volume of 4909 shares changing hands. The stock had previously closed at $27.50.

A number of analysts have commented on the stock. Oppenheimer assumed coverage on shares of Immunocore in a report on Tuesday, October 19th. They set an “outperform” rating and a $56.00 target price for the company. Zacks Investment Research upgraded shares of Immunocore from a “hold” rating to a “buy” rating and set a $32.00 price target for the company in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Immunocore has an average rating of “Buy” and a consensus price target of $50.20.

The company has a debt-to-equity ratio of 0.31, a quick ratio of 5.24 and a current ratio of 5.24. The stock’s 50-day moving average is $33.63 and its two-hundred day moving average is $34.63.

Immunocore (NASDAQ:IMCR) last issued its earnings results on Wednesday, November 10th. The company reported ($0.95) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.10) by $0.15. The company had revenue of $8.17 million for the quarter, compared to the consensus estimate of $6.92 million. On average, analysts expect that Immunocore Holdings plc will post -3.95 EPS for the current year.

Large investors have recently modified their holdings of the stock. Morgan Stanley boosted its position in shares of Immunocore by 11,505.0% during the third quarter. Morgan Stanley now owns 2,321 shares of the company’s stock worth $86,000 after acquiring an additional 2,301 shares during the last quarter. Sphera Funds Management LTD. purchased a new stake in Immunocore during the third quarter valued at $157,000. Geneos Wealth Management Inc. purchased a new stake in Immunocore during the third quarter valued at $163,000. Virtus ETF Advisers LLC purchased a new stake in Immunocore during the second quarter valued at $220,000. Finally, Geode Capital Management LLC purchased a new stake in Immunocore during the second quarter valued at $234,000. Hedge funds and other institutional investors own 44.09% of the company’s stock.

Immunocore Company Profile (NASDAQ:IMCR)

Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies.

Read More: What Is Dividend Yield and How Do You Calculate It?

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.